Susquehanna International Group
URGN icon

Susquehanna International Group’s UroGen Pharma URGN Stock Holding History

Susquehanna International Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Sell
115,800
-5,200
-4% -$104K ﹤0.01% 6098
2025
Q4 		$2.83M Sell
121,000
-50,200
-29% -$1.09M ﹤0.01% 4973
2025
Q3 		$3.42M Sell
171,200
-145,900
-46% -$2.62M ﹤0.01% 4732
2025
Q2 		$4.34M Buy
317,100
+284,300
+867% +$2.73M ﹤0.01% 4243
2025
Q1 		$363K Buy
+32,800
New +$350K ﹤0.01% 9642
2024
Q4 		– Sell
-44,600
Closed -$566K – 13288
2024
Q3 		$566K Sell
44,600
-12,900
-22% -$191K ﹤0.01% 8164
2024
Q2 		$965K Buy
57,500
+30,600
+114% +$435K ﹤0.01% 6687
2024
Q1 		$404K Buy
+26,900
New +$440K ﹤0.01% 9015
2023
Q4 		– Sell
-18,500
Closed -$259K – 13347
2023
Q3 		$259K Buy
18,500
+5,200
+39% +$83.5K ﹤0.01% 9671
2023
Q2 		$138K Buy
+13,300
New +$147K ﹤0.01% 10663
2021
Q1 		– Sell
-13,400
Closed -$241K – 12887
2020
Q4 		$241K Sell
13,400
-18,600
-58% -$390K ﹤0.01% 9728
2020
Q3 		$617K Sell
32,000
-77,900
-71% -$1.76M ﹤0.01% 7234
2020
Q2 		$2.87M Buy
109,900
+11,300
+11% +$276K ﹤0.01% 3871
2020
Q1 		$1.76M Sell
98,600
-21,400
-18% -$578K ﹤0.01% 4198
2019
Q4 		$4M Buy
120,000
+45,700
+62% +$1.25M ﹤0.01% 3288
2019
Q3 		$1.77M Buy
74,300
+58,900
+382% +$1.93M ﹤0.01% 4459
2019
Q2 		$553K Buy
15,400
+3,300
+27% +$122K ﹤0.01% 7074
2019
Q1 		$447K Buy
+12,100
New +$507K ﹤0.01% 6492
2018
Q4 		– Sell
-7,500
Closed -$354K – 10015
2018
Q3 		$354K Buy
+7,500
New +$348K ﹤0.01% 7148

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group's URGN Position: Q1 2026 in Review

Susquehanna International Group reduced its UroGen Pharma (URGN) stake by 49% in Q1 2026, selling an estimated $1.59M and leaving 83,623 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6868.

Susquehanna International Group first reported a position in URGN in Q3 2018 and has held it in 23 quarters since. The position peaked at $6.64M in Q2 2025. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Susquehanna International Group held 83,623 shares of UroGen Pharma worth $1.5M as of Q1 2026.
  • Susquehanna International Group sold 79,102 UroGen Pharma shares in Q1 2026, an estimated $1.59M.
  • UroGen Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6868 holding.
  • Susquehanna International Group first reported a position in UroGen Pharma in Q3 2018 and has held it in 23 quarters since.
  • Susquehanna International Group's UroGen Pharma position peaked at $6.64M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.